Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Sarkis K. Mazmanian | M | - |
Symbiotix Biotherapies, Inc.
 Symbiotix Biotherapies, Inc. BiotechnologyHealth Technology Symbiotix Biotherapies, Inc. develops a novel class of molecular therapeutics based on the human microbiome. It delivers first-in-class oral agents that improve the lives of patients with inflammatory bowel disease (IBD), multiple sclerosis (MS) and other serious immune-mediated diseases. The company was founded by Lloyd Kasper, Nader Yaghoubi, Sarkis Mazmanian and Dennis Kasper in 2009 and is headquartered in Boston, MA. | 15 jaar |
| Peter Alff | M | - |
Symbiotix Biotherapies, Inc.
Symbiotix Biotherapies, Inc. BiotechnologyHealth Technology Symbiotix Biotherapies, Inc. develops a novel class of molecular therapeutics based on the human microbiome. It delivers first-in-class oral agents that improve the lives of patients with inflammatory bowel disease (IBD), multiple sclerosis (MS) and other serious immune-mediated diseases. The company was founded by Lloyd Kasper, Nader Yaghoubi, Sarkis Mazmanian and Dennis Kasper in 2009 and is headquartered in Boston, MA. | - |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Nader Yaghoubi | M | - |
Symbiotix Biotherapies, Inc.
Symbiotix Biotherapies, Inc. BiotechnologyHealth Technology Symbiotix Biotherapies, Inc. develops a novel class of molecular therapeutics based on the human microbiome. It delivers first-in-class oral agents that improve the lives of patients with inflammatory bowel disease (IBD), multiple sclerosis (MS) and other serious immune-mediated diseases. The company was founded by Lloyd Kasper, Nader Yaghoubi, Sarkis Mazmanian and Dennis Kasper in 2009 and is headquartered in Boston, MA. | - |
| Sheila Mikhail | F | 57 |
Symbiotix Biotherapies, Inc.
Symbiotix Biotherapies, Inc. BiotechnologyHealth Technology Symbiotix Biotherapies, Inc. develops a novel class of molecular therapeutics based on the human microbiome. It delivers first-in-class oral agents that improve the lives of patients with inflammatory bowel disease (IBD), multiple sclerosis (MS) and other serious immune-mediated diseases. The company was founded by Lloyd Kasper, Nader Yaghoubi, Sarkis Mazmanian and Dennis Kasper in 2009 and is headquartered in Boston, MA. | - |
| Lloyd Kasper | M | - |
Symbiotix Biotherapies, Inc.
Symbiotix Biotherapies, Inc. BiotechnologyHealth Technology Symbiotix Biotherapies, Inc. develops a novel class of molecular therapeutics based on the human microbiome. It delivers first-in-class oral agents that improve the lives of patients with inflammatory bowel disease (IBD), multiple sclerosis (MS) and other serious immune-mediated diseases. The company was founded by Lloyd Kasper, Nader Yaghoubi, Sarkis Mazmanian and Dennis Kasper in 2009 and is headquartered in Boston, MA. | - |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Verenigde Staten | 5 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Dennis Kasper
- Persoonlijk netwerk
